Skip to content

Study · Non-randomized trial · n = 41 · 2013

1 result

[The role of vasoactive peptid in lower limbs chronic arterial insufficiency treatment].

Kitachov KV, Sazonov AD, Kozlov KL, Petrov KY, Slusarev AS, Sedova EV

Advances in gerontology = Uspekhi gerontologii1 Jan 2013Cited by 1 (Europe PMC)

PMID28976154 (opens in a new tab)PepBankPUB-28976154
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients who had surgery for chronic lower limb ischemia, lower limb blood flow improved significantly on clinical and ultrasonic parameters after Vezugen monotherapy compared with before treatment.

    In plain wordsIn patients after surgery for leg ischemia, Vezugen improved leg blood flow on clinical and ultrasound measures compared with before treatment.

    Peptide
    Vesugen (KED)
    Outcome
    IncreaseLower limb blood flow (clinical and ultrasonic parameters)
    Study

    n = 41

    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Blood flow in the lower limbs after treatment by Vezugen monotherapy significantly improves both on clinical and on the ultrasonic parameters.
    1 context sentence
    Summary · context
    assessment of the possibility to use the vasoactive peptid of Vezugen as monotherapy in patients underwent surgery for chronic lower limbs ischemia. The results of surgical treatment of lower limbs chronic arterial insufficiency in 41 patients were studied. A comparative analysis of clinical and ult…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 17:05 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.